Invention novelty: This invention is a novel drug composition that can target prostate tumors in vivo for use in photodynamic therapy (PDT).
Value Proposition:
Currently, prostate cancer treatment often requires invasive surgery or treatment with drugs that may cause adverse side-effects. This current technology is advantageous as it is;
• Minimally invasive
• Unlike other PDT cancer therapeutic drugs it targets the tumor, resulting in fewer side-effects.
• Can compete with immune-based drug treatments as a targeted treatment, with potentially fewer side-effects.
Technical Details:
Johns Hopkins researchers have developed a pharmacological agent for use in prostate cancer and solid-tumor
photodynamic therapy). To increase PDT efficiency, tissue-specific or tumor-specific targeting molecules are used. This technology is a molecule that specifically targets prostate cancer and potentially many-solid tumor cancer types. The synthesized molecular compound utilizes a photosensitize and a prostate targeting molecule. To date, the inventors have made and tested 2 separate molecules, which effectively and specifically target prostate tumors.
Looking for Partners: To develop and commercialize the technology as a therapeutic for prostate cancer and potentially some solid-tumor cancers.
Stage of Development: Pre-Clinical
Data Availability: Animal data available.
Patent Status: Pending
Publication(s)/Associated Cases: WO 2015/057692
Categories: Therapeutic
Keywords: Imaging, photodynamic therapy, PDT, prostate cancer, solid-tumor cancer, photosensitive,
